Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830342) titled 'A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd.
Condition:
Advanced NSCLC
Intervention:
Drug: Cyclophosphamid
Drug: Fludarabine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 2026
Target Sample Size: 12
To know more, visit https://clinicaltrials.gov/study/NCT07830342
Published by HT Digital Cont...